I did do that math wrong, but to be fair, the article is comparing apples and kumquats. $26 billion is how much Gilead has in cash, which has little to do with Sovaldi at this point. $1 billion profit (let&#x27;s say that&#x27;s annual, rather than over the life of the drug) on an $11 billion purchase would be less than 10% annual ROI. That&#x27;s very low for what was still a very risky investment (unapproved drug).